ProQR to Present at Upcoming Scientific Meeting and Investor Conference

LEIDEN, the Netherlands, Feb. 06, 2018 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced that the Company will present at an investor conference and scientific meeting during the month of February.

LEERINK Partners 7^th Annual Global Healthcare Conference

On Wednesday, February 14, 20178 at 9:30am EST, Daniel de Boer, Chief Executive Officer of ProQR, will present at the LEERINK 7^th Annual Global Healthcare Conference.  The conference is being held at the Lotte New York Palace, New York, NY.

The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30 days following the presentation date.

SMi RNA Therapeutics Annual Conference

A presentation titled “Therapeutic RNA editing by Axiomer^® editing oligonucleotides” by Janne Turunen, PhD, Director of RNA Editing Technologies at ProQR, will take place on February 21, 2018 at 11:00am GMT at the SMi RNA Therapeutics Annual Conference in London, UK.  Additional information about the conference is available online. 

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

FORWARD-LOOKING STATEMENTS 
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.:
Investor and Media Contact:
Bonnie Ortega
T: +1 858 245 3983
[email protected]